|
Market Closed -
Nasdaq
00:00:00 14/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.070 USD | -3.47% |
|
+1.51% | +3.46% |
| 10-05 | Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board | CI |
| 10-05 | BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves | MT |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,062 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 25.57% | - | - |
| Enterprise Value (EV) 1 | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,180 | 1,954 | 1,644 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 32.75% | -10.39% | -15.85% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.49x | 12.2x | 10.6x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.26x | 31,038x | 5.67x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.7x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 2.9x | 2.79x | 2.47x |
| EV / Revenue | 13.5x | 7.9x | 4.99x | 4.58x | 1.88x | 3.07x | 2.64x | 1.97x |
| EV / EBITDA | -12x | -14.6x | -16.2x | -1,592x | 4.8x | -12.6x | 9.99x | 5.83x |
| EV / EBIT | -12x | -14.4x | -15.9x | -812x | 4.82x | -4.29x | 7.9x | 5.21x |
| EV / FCF | -14.7x | -13.1x | -17x | -38.9x | 4.76x | -96.8x | 7.39x | 4.14x |
| FCF Yield | -6.81% | -7.63% | -5.88% | -2.57% | 21% | -1.03% | 13.5% | 24.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.31 | 0.6635 | 0.7615 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 710.1 | 738.7 | 834 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -173.5 | 195.7 | 281.8 |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 315.5 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -582.2 | 181.3 | 248.2 |
| Net Debt 1 | -368.3 | - | 426.7 | 507.7 | - | 117.9 | -108.5 | -418.2 |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 8.070 | 8.070 | 8.070 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 26/02/24 | 24/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.62x | 3.17x | -12.99x | -.--% | 2.14B | |
| 20.5x | 7.3x | 14.66x | 1.45% | 70.65B | |
| 27.57x | 7.54x | 23.67x | 0.05% | 51.22B | |
| 33.47x | 6.01x | 18.01x | 0.97% | 48.04B | |
| 33.77x | 3.27x | 14.13x | -.--% | 43.16B | |
| -20.11x | 203.7x | -21.41x | -.--% | 41.57B | |
| 46.41x | 5.27x | 28.96x | -.--% | 39.84B | |
| 27.3x | 7.78x | 20.18x | 0.42% | 30.87B | |
| -14.56x | 5.85x | -7.07x | -.--% | 24.08B | |
| 30.56x | 5.68x | 19.04x | -.--% | 22.2B | |
| Average | 18.13x | 25.56x | 9.72x | 0.29% | 37.38B | |
| Weighted average by Cap. | 21.68x | 28.16x | 12.94x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
